Nuevocor Closes US$45 Million Series B Financing
06 May, 2025, 13:00 CST, from Nuevocor
Today, we are excited to announce our US$45 million Series B financing co-led by Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI Pte Ltd, ClavystBio, and Boehringer Ingelheim Venture Fund, alongside HighLight Capital and SEEDS Capital. We are also pleased to welcome Amanda Gett-Chaperot, PhD (Kurma Partners) and Elia Stupka, PhD (Angelini Ventures) to our Board of Directors. This new investment will support our first-in-human, open-label, multicenter, ascending single-dose Phase 1/2 clinical trial of NVC-001 in patients with LMNA-related dilated cardiomyopathy (LMNA DCM), with clinical trial sites across the U.S. and Europe. LMNA DCM is a genetic heart condition caused by mutations in the LMNA gene, leading to the weakening and enlargement of the heart muscle, ultimately resulting in a rapid progression toward end-stage heart failure. LMNA DCM is estimated to affect more than 100,000 patients in the U.S. and Europe. We are also excited to establish an office in Paris, France, to support clinical development and bring Singapore innovation to patients globally.
